Myriad Genetics (MYGN) commends the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network, NCCN, as the guidelines underscore the critical role of the company’s portfolio of offerings across the patient’s prostate cancer journey. These guidelines further validate Myriad’s ability to streamline the diagnostic process and enhance personalized treatment options.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics initiated with a Neutral at UBS
- Myriad announces its Prolaris test is still classified as ‘Advanced Tool’
- Leerink downgrades Myriad Genetics on reimbursement, competitive headwinds
- Myriad Genetics downgraded to Market Perform from Outperform at Leerink
- Myriad Genetics Settles Shareholder Lawsuits with Reforms
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue